Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.

about

Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas

P2860

Q47683031-D668B0E0-992E-4522-AC02-B6815B1A857A Q57663772-F5481566-8F27-4765-820D-821AA5C2E55D

P2860

Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.

Item

http://www.wikidata.org/entity/Q38707076

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cross-Validation of a Glucose- ...... Patients With Type 1 Diabetes.

@en

type

Item

label

Cross-Validation of a Glucose- ...... Patients With Type 1 Diabetes.

@en

prefLabel

Cross-Validation of a Glucose- ...... Patients With Type 1 Diabetes.

@en

P1476

Cross-Validation of a Glucose- ...... Patients With Type 1 Diabetes

@en

P2093

Ajenthen Ranjan

http://www.w3.org/2001/XMLSchema#string

Carsten Boye Knudsen

http://www.w3.org/2001/XMLSchema#string

Signe Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

The UVA/PADOVA Type 1 Diabetes Simulator: New Features

Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.

In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes.

Regulation of hepatic glucose production and the role of gluconeogenesis in humans: is the rate of gluconeogenesis constant?

Postprandial and fasting hepatic glucose fluxes in long-standing type 1 diabetes.

A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.

Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.

Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System.

P304

1101-1111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1932296817693254

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Henrik Madsen

Jens Juul Holst

Sten Madsbad

John Bagterp Jørgensen

Jan Kloppenborg Møller

Sabrina Lyngbye Wendt

Kirsten Nørgaard

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28654314

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

glycobiology

P932

5951032

http://www.w3.org/2001/XMLSchema#string

Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.

about

P2860

P2860

Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932